The loss of neurons associated with such diseases as Alzheimer's and Parkinson's have long been attributed to neural degeneration. But could this degeneration actually belie underlying problems in regeneration?...
The link between mild cognitive impairment and Alzheimer's disease pathology grows stronger with a study in this month's Annals of Neurology. Kathy Riley, David Snowdon, and William Markesbery of the University of Kentucky report a strong correlation...
Despite the recent setbacks in Elan's clinical trials, vaccines still have enormous potential as therapeutic agents for a variety of disorders. As reported last week at the American College of Cardiology's 51st annual scientific session in Atlanta...
Everyone agrees: from plaques to tangles, Alzheimer's to Parkinson's, insoluble protein bodies are associated with neurodegeneration. This begs the obvious question...
Medicare recipients with a diagnosis of probable Alzheimer's disease can now receive reimbursement for physical and psychological therapy treatments...
Despite Elan's trials and tribulations, the show must go on, and many researchers are pursuing what they hope will be a better antibody for treatment of Alzheimer's disease...
Cyclooxygenase (COX), the rate-limiting enzyme in prostaglandin synthesis, is well known for its role in inflammation, but less well known for its role in neurodegeneration and cell death...
The Washington Post reported last Friday that a dozen
patients in the suspended trial of the Aβ vaccine AN-1792 have now fallen
ill with cerebral inflammation...
The Memory Evaluation and Treatment Service at Burke Medical Research Institute in New York has started a therapeutic trial of a nutritional supplement—a "metabolic enhancer"...
The Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT), a clinical research study that will test a possible link between the use of certain anti-inflammatory pain relievers and...
On February 28, 2001, the U.S. Food and Drug Administration (FDA)
approved Reminyl® (galantamine hydrobromide) for the treatment of mild to
moderate Alzheimer's disease...